UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for Parkinson's disease in the United Kingdom. Explore treatment pathways including medications, deep brain stimulation, and emerging therapies.
Parkinson's disease affects ~153,000 people in the UK and is the second most common neurodegenerative condition after Alzheimer's. It causes tremor, slowness of movement, stiffness, and balance problems, along with non-motor symptoms (sleep problems, mood changes, constipation). There is currently no cure, but treatments can significantly improve quality of life.
First-line: levodopa (with carbidopa/benserazide) remains the gold standard. Other options: dopamine agonists (pramipexole, ropinirole), MAO-B inhibitors (rasagiline, selegiline), and COMT inhibitors (entacapone, opicapone). Advanced disease: deep brain stimulation (DBS), apomorphine infusion, or levodopa-carbidopa intestinal gel (LCIG). Physical therapy, occupational therapy, and speech therapy are essential.
Exciting new approaches: focused ultrasound (MRI-guided, non-invasive brain surgery for tremor), gene therapy (targeting GAD or AADC), alpha-synuclein immunotherapy (targeting the protein that clumps in Parkinson's), stem cell replacement therapy, and wearable AI monitoring devices for better symptom tracking.
The UK is a global leader in Parkinson's research through Parkinson's UK and the National Institute for Health Research. Active trials include: disease-modifying therapies, neuroprotective agents, repurposed drugs (exenatide, simvastatin), digital biomarkers, and precision medicine approaches based on genetic profiling (LRRK2, GBA mutations).
Free AI-powered matching - no signup required
Search PD Trials →